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AbstrAct
Introduction Medicines optimisation is a key role for hospital 
pharmacists, but with ever-increasing demands on services 
there is a need to increase efficiency while maintaining 
patient safety. The aim of this study is to develop a prognostic 
model, the Medicines Optimisation Assessment Tool (MOAT), 
which can be used to target patients most in need of 
pharmacists' input while in hospital.
Methods and analysis The MOAT will be developed 
following recommendations of the Prognosis Research 
Strategy partnership. Using a cohort study we will 
prospectively include 1500 adult patients from the medical 
wards of two UK hospitals. Data on medication-related 
problems (MRPs) experienced by study patients will be 
collected by pharmacists at the study sites as part of their 
routine daily clinical assessment of patients. Data on potential 
risk factors such as polypharmacy, renal impairment and the 
use of 'high risk' medicines will be collected retrospectively 
from the information departments at the study sites, 
laboratory reporting systems and patient medical records. 
Multivariable logistic regression models will then be used 
to determine the relationship between potential risk factors 
and the study outcome of preventable MRPs that are at least 
moderate in severity. Bootstrapping will be used to adjust 
the MOAT for optimism, and predictive performance will be 
assessed using calibration and discrimination. A simplified 
scoring system will also be developed, which will be 
assessed for sensitivity and specificity.
Ethics and dissemination This study has been approved 
by the Proportionate Review Service Sub-Committee of the 
National Health Service Research Ethics Committee Wales 
REC 7 (16/WA/0016) and the Health Research Authority 
(project ID 197298). We plan to disseminate the results 
via presentations at relevant patient/public, professional, 
academic and scientific meetings and conferences, and will 
submit findings for publication in peer-reviewed journals.
Trial registration number NCT02582463.
IntroductIon
Medicines play a crucial role in maintaining 
health and are the most common interven-
tion in healthcare. However, in the UK, as 
elsewhere, there is a growing body of evidence 
that there is a need to improve medicines 
use.1–6 This includes the Francis and Berwick 
reports,1 2 which call for a number of actions 
to improve patient safety and reduce avoid-
able harm.
Historically, adverse drug events have been 
the focus of studies of medication-related 
harm,7 but problems can also result from 
suboptimal medicines use, such as ineffec-
tive treatments or subtherapeutic doses. It is 
estimated that only 4%–21% of patients in 
primary care receive optimum benefit from 
their medicines,8 and it has been suggested 
that research efforts should also identify 
patients with unrealised benefits.9 A term that 
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Protocol
Strengths and limitations of this study
 ► The Medicines Optimisation Assessment Tool 
(MOAT) will be the first evidence-based prognostic 
model to identify hospitalised patients at risk of 
moderate or severe medication-related problems in 
order to permit targeting by pharmacists.
 ► The study will include adult patients of all ages 
admitted to all types of medical wards (general, 
emergency and elderly medicine), so will be 
representative of patients routinely admitted to 
hospital medical wards.
 ► The method and analysis plan are based on 
the  Prognosis Research Strategy, Transparent 
Reporting of a multivariable prediction model for 
Individual Prognosis Or Diagnosis (TRIPOD) and 
CHecklist for critical Appraisal and data extraction 
for systematic Reviews of prediction Modelling 
Studies (CHARMS) recommendations for prognostic 
research.
 ► The study is observational, which may be subject to 
reporting bias and missing data.
 ► Only two hospitals will be included in the study; 
further validation, impact and implementation 
studies will be needed to determine whether the 
MOAT could be successfully employed in new 
settings.
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encompasses both aspects is medication-related problems 
(MRPs), defined as all circumstances involving a patient’s 
drug treatment that actually, or potentially, interfere with 
the achievement of an optimal outcome.7 10–12 This also 
shifts the focus from ‘medication-related harm’ to ‘medi-
cines optimisation’, which can be described as the safe 
and effective use of medicines to enable the best possible 
outcomes.5 Medicines optimisation is high on the English 
national agenda, with guidance issued by the Royal Phar-
maceutical Society and the National Institute for Health 
and Care Excellence.4 5
Medicines optimisation is a key role for pharma-
cists,13–16 and a number of systematic reviews conclude 
that addition of clinical pharmacy services to the care 
of hospital inpatients improves quality, safety and effi-
ciency of patient care.10 17 18 Ideally, pharmacists would 
see every patient daily, but medicines optimisation is 
not the only goal for hospital pharmacy services in 
England.13 19 Other service developments are required, 
such as delivery of 7-day services20 and the Hospital Phar-
macy Transformation Programme, as set out in the recent 
review by Lord Carter on improving productivity and 
performance in English National Health Service (NHS) 
acute hospitals.21 Owing to financial challenges that face 
the NHS, these developments often have to be achieved 
within existing funding through increased efficiency and 
innovation.5 22 23 There have therefore been calls from 
international government organisations and professional 
bodies for effective ways for pharmacy services to target 
patients most in need.15 24–28
Clinical prioritisation has been proposed as a way to 
permit pharmacy services to focus on the greatest need 
and where clinical pharmacy input is likely to have greatest 
impact. This requires a method to triage patients to 
assign ‘pharmaceutical acuity’.28 29 There are recognised 
risk factors for MRPs, for example polypharmacy, renal 
impairment and the use of ‘high risk’ medicines,30 but to 
target patients appropriately pharmacists need to be able 
to apply this knowledge effectively and consistently within 
their routine clinical practice.
Predicting clinical risk is well established in medicine. 
Tools such as cardiac-risk calculators and the Waterlow 
score (to assess the risk of pressure ulcers) are both used 
daily across the NHS.31 32 Prediction tools to identify 
hospitalised patients at risk of adverse medication-related 
outcomes have been developed,33–41 but the majority 
identify patients at risk of adverse drug reactions,34 35 
adverse drug events36 or medication errors,37 rather than 
MRPs, or are based on ‘expert opinion’ rather than statis-
tical determination.38–41
Interest in prediction research (also known as prog-
nosis research) has developed rapidly in recent years. 
It involves use of statistical methods to predict future 
health outcomes among people with a given baseline 
health status, and therefore has potential to inform clin-
ical decision making, improve patient care and make 
healthcare more efficient.42 43 Prognostic modelling is 
one component of prognosis research, in which multiple 
risk (prognostic) factors are statistically combined to 
predict future clinical risk for an individual patient.44 
However, many published prognostic model studies have 
been criticised in terms of methodological shortcom-
ings, limiting their reliability and applicability,44 45 as well 
as poor reporting, which limits the ability to effectively 
assess the risk of bias.43 46 Both problems ultimately limit 
the usefulness of the prognostic models. The perceived 
inadequacies in prognostic model research prompted the 
recent publication of recommendations for prognosis 
research by the Prognosis Research Strategy (PROGRESS) 
partnership,42 44 47 48 together with specific guidelines for 
reporting43 46 and critically appraising49 prognostic model 
research.
This study aims to address a current gap in the evidence 
base: the development of a methodologically sound prog-
nostic model to target hospital patients most in need 
of pharmacists’ input based on their risk of MRPs. The 
purpose of publishing this study protocol is to expand on 
the details already publicly available50 to clearly specify 
a priori the outcome measure, prognostic factors and 
analysis plan. This is intended to protect against both 
data-driven model development (associated with overop-
timistic model performance) and selective reporting. The 
study method is informed by the PROGRESS guidelines, 
and the protocol includes the key elements proposed by 
Peat et al43 for inclusion in prognostic model protocols, 
and follows the Transparent Reporting of a multivariable 
prediction model for Individual Prognosis Or Diagnosis 
(TRIPOD) Statement guidance46 and the CHecklist 
for critical Appraisal and data extraction for systematic 
Reviews of prediction Modelling Studies (CHARMS) 
checklist49 in terms of the level of detail provided. This 
is to ensure provision of sufficient information to permit 
full assessment of risk of bias and applicability.
The aim of this study is to develop a prognostic model, 
the Medicines Optimisation Assessment Tool (MOAT), 
to identify adult patients at highest risk of preventable, 
moderate or severe MRPs during admission to a UK 
medical ward. Additional objectives are to assess the 
MOAT’s content validity, feasibility of use, potential effi-
ciency savings and the potential clinical risk associated 
with false-negative predictions. The proposed purpose of 
the MOAT is to permit appropriate targeting of patients 
by pharmacy staff in order to reduce risks, improve 
patient outcomes and increase efficiency of hospital clin-
ical pharmacy services, thereby supporting delivery of 
national targets related to patient safety, medicines opti-
misation and service provision.
Methods and analysIs
design
This is a prognostic model development study that aims 
to select candidate predictors (the potential prognostic 
factors) and combine them into a multivariable model 
using logistic regression. Internal validation (bootstrap-
ping) will be used to evaluate the performance of the 
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model and permit adjustment for optimism. The MOAT 
will be developed using a prospective cohort study 
involving adults admitted to the medical wards at two UK 
hospitals in South East England. Two study sites, Hospi-
tals A and B, were chosen to increase generalisability of 
the MOAT as they have markedly different patient demo-
graphics. It is anticipated that the study will be completed 
by April 2018.
eligibility criteria
Patients aged 18 years old or over will be selected by 
means of being consecutive admissions to the medical 
wards (general, emergency and elderly medicine) at the 
two study sites during the study period. Patients admitted 
to other specialties such as surgery, maternity and paedi-
atrics will be excluded due to potential differences in the 
prevalence/type of MRPs in these patient groups.
Patients will be excluded if:
 ► their admission is for investigation only (as changes 
to medication will be minimal)
 ► they are not prescribed any medication during the 
admission
 ► their entire admission is outside of core pharmacy 
working hours (ie, 09:00–17:00 Monday–Friday) 
as these patients are unlikely to receive review by a 
clinical pharmacist
 ► their prescription is not reviewed by a clinical 
pharmacist during the admission (eg, a patient who 
is present on a study ward during core pharmacy 
working hours but discharged before a clinical 
pharmacist is able to review his/her medication).
outcome
The outcome of interest for the prognostic model-
ling will be MRPs that are at least moderate in severity 
and preventable. Research has shown that a significant 
proportion of hospitalised patients will experience MRPs 
(eg, Blix et al51 reported a rate of 81%), many of which 
are of limited clinical significance. We will therefore use 
moderate or severe MRPs as this will enable the MOAT to 
target patients most in need of pharmacist input in terms 
of risk of medication-related harm or suboptimal use. It 
will also ensure that the MOAT is clinically relevant and 
feasible to implement in terms of pharmacists’ workload. 
Similarly, only MRPs considered as ‘preventable’ will be 
considered to ensure that the MOAT identifies patients 
with MRPs that are amenable to pharmacist intervention 
either directly or through discussion with prescribers.
The definition for MRPs that will be used is ‘all 
circumstances involving a patient’s drug treatment that 
actually, or potentially, interfere with the achievement of 
an optimal outcome’.7 10–12
All MRPs will be classified for descriptive reporting 
purposes. As there is no universally accepted classifica-
tion system and perceived deficiencies with some systems, 
we will use the aggregated classification system recently 
developed by Basger et al.52 This provides a comprehen-
sive classification system based on the causes of MRPs, 
thereby preventing any potential confusion between MRP 
‘causes’ and ‘outcomes’.
MRP data will be identified and recorded by pharma-
cists at the study sites as part of their routine daily clinical 
assessment of patients. They will record data on all MRPs 
identified personally or through discussion with other 
healthcare professionals. The hospital incident reporting 
systems will also be reviewed to check for any additional 
significant MRPs that are not identified by pharmacy staff. 
Following training on the use of Basger’s aggregated clas-
sification system, pharmacists will be asked to classify each 
MRP at the point of identification.
MRP data will be collected for all study patients from 
admission to discharge from hospital, or the date the 
study closes (2 weeks after inclusion of the final study 
patient), whichever occurs sooner. A study close date will 
be used to facilitate practicality in terms of data collection, 
while permitting data to be collected from admission to 
discharge for the majority of study patients (as the mean 
length of stay at the study sites is approximately 6 days).
Previous research into the detection of prescribing 
errors, a subset of MRPs, has shown that the observed 
incidence is extremely dependent on the method of 
detection.53 We have chosen to use prospective identifica-
tion by pharmacists for this study because (1) the purpose 
of the study is to develop a prognostic model for MRPs 
that can be identified during routine clinical practice by 
pharmacists; (2) it will permit the identification/inclu-
sion of MRPs that are not routinely recorded in medical 
notes, such as potential prescribing or administration 
errors that are intercepted; and (3) it will permit the 
MRPs to be identified by staff personally involved in the 
care of the study patients, increasing clinical and practical 
relevance.
It is acknowledged that a limitation will be the possibility 
of incomplete data due to pharmacy staff being required 
to complete this work in addition to other routine duties. 
To minimise this, the principal investigator will work 
closely with the study sites to ensure that data collection 
occurs at an optimal time in terms of staffing levels and 
workload. Staff involved in MRP data collection will also 
be provided with initial training to improve the consis-
tency and reliability of data collection. The principal 
investigator will review all data collection forms daily and 
seek clarification where needed, and provide the pharma-
cists with ongoing fidelity training.
We also recognise that identification of MRPs may vary 
depending on the knowledge, experience and skills of 
the pharmacists collecting data. To quantify this poten-
tial variability, a simulated ‘MRP identification assessment 
exercise’ will be developed and used in a training 
scenario. Each simulated MRP will be treated as having a 
binary outcome in terms of whether or not it is identified 
by each pharmacist. Fleiss’ kappa will be used to calculate 
the level of agreement between pharmacists.
In prognostic research it is recommended that the 
outcome is assessed while blinded to the candidate predic-
tors (potential prognostic factors) to prevent bias.49 54 55 
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In this study it will not be possible to blind the pharma-
cists collecting the outcome data to the patient’s clinical 
information (such as age, diagnosis, laboratory results 
and so on) as this information will form part of their 
clinical assessment of the patient. Despite this, the phar-
macists collecting the outcome data will not know which 
factors will be used as candidate predictors in order to 
minimise the potential for this information to influence 
their outcome assessment.
Following anonymisation to maintain patient confiden-
tiality and blinding, each potential MRP will be assessed by 
an expert panel. Agreement will be reached by consensus 
on whether it is a true MRP, and then confirmed MRPs will 
be assessed for severity. The expert panel will comprise 
the principal investigator, a hospital pharmacist, a senior 
nurse and a consultant physician. Once MRPs have been 
confirmed, the panel will assess each MRP for severity. 
As no established grading for MRPs is available, severity 
will be classified using a validated visual analogue scale 
for medication errors,56 used previously for this purpose 
by Rashed et al.57 MRPs will be scored independently in 
terms of potential patient outcomes on a scale of 0–10, 
where 0 represents a case with no potential adverse effect 
on the patient and 10 a case that would result in death. 
The mean score for each MRP from the panel members 
will be used as an index of severity, with a score of less than 
3 being considered as a minor outcome (very unlikely to 
have an adverse effect), a score of 3–7 will be considered 
as moderate (likely to cause some adverse effects or inter-
fere with therapeutic goals, but very unlikely to result in 
death or lasting impairment), and a score of greater than 
7 will be considered to be a severe outcome (likely to 
cause death or lasting impairment).
No established grading system for MRP preventability 
is available; therefore, we considered two possible 
methods: the criteria provided by Schumock and 
Thornton,58 and the ‘P Method’.59 We concluded that 
both methods were developed for adverse drug reac-
tions, most of which are unpreventable, whereas the 
majority of MRPs are inherently preventable. Neither 
method was therefore appropriate for the present study. 
Pharmacists will therefore be asked to review each MRP 
at the point of identification to assess whether it was 
preventable, expressed as a dichotomous variable of 
yes or no. The principal investigator will then perform 
a second check of all MRPs to ensure consistency. To 
prevent ‘judgement drift’ a ‘case law document’ will be 
used.60
candidate predictors
Candidate predictors are the variables that predict the 
prognostic outcome. These can include patient demo-
graphics, clinical history, physical examination, disease 
characteristics, test results and treatments used.
When choosing the potential candidate predictors, 
various recommendations have been made:
 ► Predictors already reported as prognostic should be 
included.61 62
 ► The selection should be informed by clinical 
understanding (ie, expert opinion) to ensure the list 
is comprehensive and clinically relevant.45 62
 ► Where predictors are highly correlated (eg, weight 
and body mass index), only one should be selected.62
 ► Potential confounders (ie, a variable that may be 
associated with another predictor and the outcome) 
should be included to permit these to be accounted 
for during analysis.63
 ► Use of predictors that occur infrequently can lead to 
inaccurate results.62 64
 ► Candidate predictors should be:
 ► available at the time when the model is intended 
to be used.54
 ► clearly defined, standardised and reproducible 
(to enhance generalisability and applicability of 
study results to practice).54
 ► have minimal measurement error (as this may 
dilute their prognostic value).49
A review of the published literature identified 59 possible 
predictors, but substantial variations were found between 
studies in terms of the strength of evidence for each 
predictor. This is potentially due to significant differences 
in study design, and the outcome measure used (namely 
adverse drug events, adverse drug reactions, prescribing 
errors and MRPs). Twenty-seven of the potential predic-
tors were selected, based on the strength of published 
evidence in addition to the criteria stated above, for inclu-
sion in a survey to obtain expert opinion from healthcare 
professionals and patient/public representatives. The 
survey was administered during April–June 2016, and a 
total of 247 responses were received. The results showed 
that the majority of the potential predictors (23 of 27) 
were considered ‘important’ or ‘very important’. In addi-
tion, a significant number of additional predictors (59) 
were suggested.65
When developing a prognostic model, it is necessary to 
limit the number of candidate predictors used to prevent 
‘overfitting’ or ‘underfitting’. Both can lead to poor 
performance when the model is used in an independent 
data set.55 One method to reduce the number of candi-
date predictors is to base the selection on the univariable 
association between each predictor and the outcome. 
This is not recommended as it results in overfitting due to 
selection bias,61 and can lead to predictors being wrongly 
excluded from the model due to the fact that the associa-
tion may only become significant after adjustment for the 
other predictors. It is recommended that the candidate 
predictors are selected a priori.47 64 We have therefore 
chosen to preselect the candidate predictors for develop-
ment of the MOAT (table 1) using the recommendations 
above. An additional consideration was the selection of 
predictors that form part of standard clinical data sets. 
This was to increase the reliability of the data and mini-
mise the potential for missing data, and to enable the 
MOAT to be readily incorporated into clinical practice 
without the need for additional tests/measurements.
group.bmj.com on June 19, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Geeson C, et al. BMJ Open 2017;7:e017509. doi:10.1136/bmjopen-2017-017509
Open Access
Table 1 Preselected candidate predictors for the Medicines Optimisation Assessment Tool
Variable Details/categories Type of measurement
Number of 
variables*
Demographic
  Age Age at admission to hospital (in years) Continuous numeric 1
  Socioeconomic status Based on the English indices of deprivation 
2015 (Index of Multiple Deprivation Rank)
Continuous numeric 1
Patient-related
  Previous allergy/adverse 
drug reaction
Yes/No Binary 1
  Body mass index First documented result following admission Continuous numeric 1
  Number of hospital 
admissions
Number of admissions to the study hospital in 
the previous 6 months
Continuous numeric 1
  Primary diagnosis Categorised by ICD-10 coding:
 ►Endocrine
 ►Nutritional and metabolic diseases
 ►Diseases of the circulatory system
 ►Diseases of the respiratory system
 ►Diseases of the digestive system
 ►Diseases of the genitourinary system
 ►Other (all other diagnoses combined)
Nominal categorical 6
  Number of comorbidities From hospital clinical coding data (ICD-10 
codes)
Continuous numeric 1
  History of dementia From hospital clinical coding data (ICD-10 
codes)
Binary 1
Medicines-related
  Number of medicines 
prescribed
Number of ‘regular’ medicines prescribed on 
the first full day of admission to hospital (ie, 
excluding ‘when required’ and ‘once only’ 
medicines, dietary products, non-medicated 
topical products (eg, emollients), wound 
dressings)
Continuous numeric 1
  Use of ‘high risk medicines’ Prescribed as a ‘regular’ medicine during the 
hospital admission:
 ►Anticoagulants/direct oral anticoagulants
 ►Therapeutic heparin
 ►Antidiabetic medication
 ►Opiates (excluding codeine, tramadol and 
dihydrocodeine)
 ►Aminoglycosides and glycopeptides
 ►Antibiotics (excluding aminoglycosides and 
glycopeptides)
 ►Theophylline and aminophylline
 ►Epilepsy medicines
 ►Antipsychotics
 ► Immunosuppressants (excluding 
corticosteroids)
 ►Cytotoxics
 ►Lithium
 ►Antiarrhythmics
 ►Antidepressants
 ►Other (clozapine, antiretrovirals, medicines 
for Parkinson’s disease)
Binary (for each group) 15
Continued
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All data on the candidate predictors will be collected 
retrospectively. Data will be obtained from the informa-
tion department at the study hospitals where possible, 
including demographic, diagnostic and comorbidity 
data. Laboratory data will be extracted manually from the 
electronic reporting system used at both hospitals. The 
remaining data will be extracted manually from patient 
medical records. Hospital A has electronic medical 
and prescribing records; Hospital B has paper-based 
systems. Manual data extraction of laboratory data will be 
performed by a single data analyst at each study site, inde-
pendently of the research team. Data from the patient 
medical records will be collected by the independent data 
analyst at Hospital A, but due to the use of paper-based 
systems at Hospital B and the need to read handwritten 
prescriptions, these data will be extracted by the principal 
investigator at Hospital B. All manually extracted data will 
be entered directly into an electronic database. All data 
will be recorded as reported, with no categorisation of 
continuous data.
In prognostic research it is recommended that data 
on candidate predictors is collected blind, in terms of 
knowledge of the outcome and other predictors.49 55 This 
is particularly important when subjective judgement is 
required as it prevents the assessment being influenced, 
which could artificially increase the associations between 
the predictors and outcomes. Full blinding will not be 
possible for this study as the independent data analysts 
and the principal investigator will not be blinded to all 
other predictor data, and the principal investigator will 
not be blinded to the MRP status. It is anticipated that this 
will have minimal impact on the accuracy of data collec-
tion as all candidate predictors selected for this study 
are objective measurements that are independent of 
observer interpretation; therefore, subjective judgement 
is not required. In addition all candidate predictors will 
be recorded contemporaneously during the admission as 
part of routine care/documentation, therefore without 
knowledge of the MRP status. To identify any possible 
bias, the principal investigator will perform a double 
check on data entry. This will involve a double check 
on a randomly selected 10% sample of the 1500 study 
patients. Sixteen data items will be checked for each of 
these 150 patients, giving a total of 2400 data items. The 
accuracy will be calculated as the percentage of data items 
recorded correctly. Data entry will be refined if necessary.
Sample size calculation
Sample size is often calculated based on significance 
testing (power calculations), but this is not straightfor-
ward for prognostic modelling studies as there is often 
not a clear ‘measure of effect’ to power the research. An 
Variable Details/categories Type of measurement
Number of 
variables*
  Parenteral administration 
route
Administration of one or more regular 
medicines via the parenteral route 
(intravenous, intramuscular, subcutaneous) 
during the hospital admission (excluding 
prophylactic low molecular weight heparins, 
fluid replacement therapy)
Binary 1
Laboratory results
  Renal function Creatinine clearance calculated using 
the Cockcroft-Gault equation (using first 
documented results following admission)
Continuous numeric 1
  Liver disease Liver disease defined as ALT/ALP and/
or bilirubin ≥3 times normal range and/or 
documented liver disease
Laboratory results will be the first documented 
results following admission
Documented liver disease will be established 
from hospital clinical coding data (ICD-10 
codes)
Binary 1
  Serum albumin First documented result following admission Continuous numeric 1
  Serum potassium First documented result following admission Continuous numeric 1
  Serum sodium First documented result following admission Continuous numeric 1
  White cell count First documented result following admission Continuous numeric 1
  Platelet count First documented result following admission Continuous numeric 1
Total number of variables* 37
*Number of variables in relation to calculating the ‘events per variable’.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; ICD, International Statistical Classification of Disease and Related Problems.
Table 1 Continued 
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alternative method is to calculate the sample size based 
on the desired precision of a sample estimate.55 An alter-
native approach that is commonly used is the ‘rule of 
thumb’ of '10 events per variable’ (EPV).66 This method 
requires the sample size to be based on the prevalence 
of the outcome measure and the number of candidate 
predictors that will be used in model development.49 54 55 66 
Although there is debate over the optimal number of EPV, 
with recognition that ‘the rule of 10 or more EPV is not a 
well-defined bright line’,64 there is agreement that models 
developed with less than 10 EPV need to be interpreted 
with caution.55 64 The reason for the potential problem 
with using less than 10 EPV relates to the reliability of the 
model when used in a new group of patients. If a model 
is too closely adapted to the developmental data, it can 
reflect associations between the candidate predictors and 
outcome which are due to chance rather than true associ-
ations, known as ‘overfitting’ or ‘optimism’.49 55 61
For this study the sample size has been dictated by 
practical considerations (funding, time available and 
accessibility of data at the study sites), resulting in the 
capacity to include 1500 (1000 from Hospital A and 500 
from Hospital B), plus an additional 10% per site to allow 
for exclusion of patients who do not meet the eligibility 
criteria. We have therefore used both the precision and 
EPV methods to consider the adequacy of this sample 
size, based on an estimation of the outcome prevalence 
in the study population.
The outcome of interest for this study is moderate or 
severe, preventable MRPs in hospitalised UK patients. 
No estimate for the prevalence of this outcome currently 
exists, but Blix et al51 (Norway 2004) reported that 81% 
of 827 hospitalised patients experienced an MRP, with 
approximately half of all MRPs classified as ‘extremely 
important’ or ‘major’ in terms of clinical significance 
(preventability not reported). To establish the prevalence 
of the outcome in the study population, we carried out 
pilot work involving 200 patients, and found that 39% 
(95% CI 32% to 45%) experienced at least one moderate 
or severe, preventable MRP (using the proposed visual 
analogue scale for medication errors and a severity score 
of 3 or more). Although this is consistent with Blix’s work, 
we recognise that our estimate is based on a small sample 
of patients (200). In addition the MRPs were severity 
rated by three members of the expert panel rather than 
the four proposed for the main study. We have there-
fore chosen to use the lower CI limit as an estimate of 
the outcome prevalence, that is, 32%. Given an antici-
pated outcome prevalence of 32% and a sample of 1500 
patients, we anticipate identifying 480 patients with at 
least one moderate or severe preventable MRP.
To consider the adequacy of the sample size using the 
precision method, we first established acceptable target 
sensitivity for the MOAT by including a question in our 
survey of healthcare professionals and patient/public 
representatives, detailed above. We proposed a target 
sensitivity of 90% and asked survey respondents if this was 
acceptable. This sensitivity was selected based on previous 
research to develop a ‘clinical decision rule’ to identify 
emergency department patients at risk of adverse drug 
events.67 Hohl et al67 used a target sensitivity of 90% as 
this was deemed acceptable by emergency physicians 
and considered feasible for implementation in terms of 
workload for pharmacists. A total of 237 responses were 
received for this question: 189 (80%) answered that 90% 
was an acceptable target, 21 (9%) answered no and 27 
(11%) were ‘unsure’. As a result we concluded that 90% 
is an acceptable target for sensitivity. Given the antici-
pated number of study outcomes and a target sensitivity 
of 90%, this will permit the precision of the sensitivity to 
be estimated with 95% CIs of ±3%, which we consider to 
be an acceptable level of precision in terms of clinical 
usefulness of the MOAT.
For the EPV method our aim would be to have at least 
10 events for every variable used in model development. 
Given the estimate of 480 outcome events, that is to say 
patients with at least one moderate or severe preventable 
MRP, this would permit the inclusion of 48 ‘variables’ in 
model development. The number of variables includes 
all proposed candidate predictors, interactions exam-
ined (ie, where a candidate predictor has a different 
association with the response depending on the value of 
a third variable), transformations for continuous predic-
tors (which permits modelling of non-linear predictors) 
and indicator variables for categorical predictors. We do 
not hypothesise any interactions a priori. We will explore 
any potential interactions during the analytical stage to 
establish whether there are associations that may lead to 
a better understanding of the final model, but recognise 
the risk of overfitting caused when numerous interactions 
are examined, with only the strongest included in the 
model.55 Similarly, we will not know whether transforma-
tions are required until we examine the linearity of the 
continuous predictors.
Table 1 shows the total number of variables that will 
be used for each candidate predictor (including the indi-
cator variables, which are the artificial variables used to 
represent distinct groups within a categorical variable). 
We propose using 37 variables to develop the MOAT, 
resulting in 13 EPV, given that no interactions or transfor-
mations are required.
data analysis plan
Descriptive analysis
Descriptive information about the sample population 
will be provided. This will include the distribution of 
the relevant characteristics of study patients, including 
demographic data, the distribution of candidate predic-
tors, the ranges of continuous predictors and the amount 
of missing data (with possible reasons for the missing-
ness). This is to permit an assessment of the context, case 
mix and setting of the study; the ranges of continuous 
predictors that are compatible with the MOAT; and the 
potential impact of any missing data. Descriptive informa-
tion will also be provided on the proportion of patients 
with MRPs, including the severity and preventability. We 
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will also report the outcome frequency (namely patients 
with at least one MRP that is moderate or severe and 
preventable) across the predictor categories.
Statistical analysis
The data analysis plan has been developed prior to any 
analysis of the study data to prevent the potential for 
data-driven model development and type 1 errors.47 The 
study method is informed by the recommendations of the 
PROGRESS partnership42 44 47 48; however, it is recognised 
that a prognostic research protocol cannot be a ‘rigid 
blueprint’. Peat et al43 state that it is neither possible nor 
desirable to prespecify all analysis. We therefore acknowl-
edge that it may be necessary to modify the analysis plan 
or carry out additional analyses in light of new findings. 
Analysis will be conducted using SPSS V.24.
Missing data
Complete-case analysis can lead to selection bias55 68 
and loss of statistical power/precision.61 We will there-
fore examine missing data to establish the missingness 
mechanism, and if we can establish that the data are 
‘missing at random’ we will use multiple imputation 
(using ≥20 imputed data sets) to impute the missing 
values. We will then carry out complete-case analysis and 
compare the results with those from multiple imputation 
to assess for potential bias due to data that are ‘missing 
not at random’.
Candidate predictor handling
We will first review the measurement reliability of each 
candidate predictor and consider excluding any that are 
found to be unreliable.55 We will also consider if there 
are any closely related predictors that may need to be 
combined, or one excluded from the analysis.55 All candi-
date predictors that are measured as continuous variables 
will be analysed on their continuous scale, that is we will 
not dichotomise or use categorisation as this can lead to 
optimistic model performance.47 49 55 61 We have chosen 
to treat liver disease as a binary variable (see table 1), 
but this is because of the variation in liver function tests 
dependent on the type and stage of disease, and to be 
consistent with pharmacy prioritisation tools currently 
in use in the UK.28 Individual continuous predictors will 
be examined to identify/investigate unexpected values 
in order to establish if they are recording errors or true 
outliers. We will also check for linearity of continuous 
predictors and use appropriate data transformation if 
required.69 For categorical variables we will review the 
number of patients within each group and consider the 
need to collapse groups if there are insufficient patients 
to permit robust modelling.61
Model building
We will use multivariable logistic regression modelling to 
develop the MOAT. This has been chosen as the outcome 
is binary, and all participants will be followed up to the end 
of the study period. The aim is to produce a parsimonious 
model to increase clinical applicability while retaining 
reasonable predictive performance.
Backwards elimination will be used to reduce the 
set of candidate predictors. The Akaike Information 
Criterion (AIC) will be used to exclude predictors. We 
chose to use the AIC due to the relatively small data set 
(hence relatively larger p values for the predictors), as 
it is less likely to result in underfitting than alternative 
methods.69
Adjusting for optimism
The predictive performance of prognostic models is 
overestimated when assessed using the same sample data 
used in development (known as the apparent perfor-
mance), simply because the model has been optimised 
for that data. To account for this ‘optimism’, we will assess 
the predictive performance of our original model using 
bootstrap validation. Steyerberg69 advises that 100–200 
bootstraps may be sufficient; therefore, we plan to use 
200, but will increase this if it is needed to achieve a stable 
estimate. We can then use this to calculate a ‘shrinkage 
factor’, which will be used to adjust our original model to 
produce the final model/MOAT.
Creating a simplified scoring system
The final prognostic model will be used to develop a 
simplified scoring system or ‘clinical decision rule’. 
These differ from prognostic models in that they indicate 
a specific course of action, rather than simply providing 
an estimate of risk, and have the advantage that they are 
simpler to use in clinical practice as they do not require 
complex calculations.
We will use the method developed by Sullivan et al70 
to convert the regression coefficients from the final 
prognostic model into a score. We will then create ‘risk 
groups’ (high, medium and low) based on the scoring 
system.
The development of the scoring system for the MOAT 
will require categorisation of the continuous predictors 
and the selection of appropriate cut-off points for the 
risk categories; we will therefore seek input from clinical 
experts to ensure that the grouping is clinically practical 
and appropriate.
Assessing model performance
We will assess the predictive performance of the final 
prognostic model using calibration (agreement between 
observed and expected predictions) and discrimination 
(the ability to differentiate between those who do or do 
not experience the outcome event). The calibration will 
be presented as a graph of the predicted risk of experi-
encing a preventable, moderate or severe MRP versus the 
observed risk in the study sample. Discrimination will be 
reported as the area under the receiver operating charac-
teristic curve.
The predictive performance of the simplified MOAT 
scoring system will be reported using the classification 
measures: sensitivity and specificity.
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Future plans
The intention of this research is to develop a prognostic 
model with potential to be adopted widely into clinical 
practice. This requires the MOAT to be clinically cred-
ible, accurate, generalisable and clinically effective in 
improving decision making and patient outcomes.71
If the initial research is successful in producing a model 
with good predictive performance, we plan to conduct 
further research to assess content validity, feasibility of 
use, potential efficiency savings and any potential clinical 
risk to patients through use of the MOAT due to false-neg-
ative predictions.
Extensive external validation, involving prospective 
validation in a new cohort, will also be required to further 
assess accuracy and generalisability before routine use 
of the MOAT could be recommended.44 External valida-
tion will also provide opportunity to refine the MOAT in 
terms of improving the accuracy such as by updating the 
model44 72 and/or simplifying the scoring system.
Following external validation we also plan to carry 
out implementation and impact studies to establish 
whether the MOAT has advantages over current prac-
tice, is compatible with (and can easily be incorporated 
into) practice, has the potential to change pharmacists’ 
behaviour, has a positive impact on patient outcomes and 
is cost-effective. We would also investigate the possibility 
of incorporating the MOAT into a computerised alerting 
system, which would permit accurate, automated risk 
assessments in ‘real-time’, which would further support 
implementation.
conclusIon
To the best of our knowledge, the MOAT will be the 
first evidence-based clinical prioritisation tool to identify 
patients most in need of pharmacists’ input (in terms of 
their risk of moderate or severe, preventable MRPs) while 
in hospital. The current research aims to develop a clin-
ically credible and accurate prognostic model. Although 
further validation will be needed, we believe that the 
MOAT will have the potential to support pharmacists’ 
decision making by providing objective assessments of 
patients’ risk, thereby ultimately improving efficiency and 
safety.
ethIcs and dIsseMInatIon
This study has been approved by the Proportionate Review 
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disseminate the results via presentations at professional, 
academic and scientific meetings and conferences, and 
will submit the findings for publication in a peer-reviewed 
journal, adhering to the Strengthening the Reporting of 
Observational Studies in Epidemiology guidelines for the 
reporting of observational studies.73 We will also present 
our findings at relevant patient/public meetings at the 
study sites, and work with the patient and public members 
of the project steering group to develop a wider public 
dissemination strategy.
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